Biogen to Present New Data at 2024 CTAD Conference
CAMBRIDGE, Mass., Oct. 24, 2024—Biogen Inc. (Nasdaq: BIIB) revealed its schedule for data presentations and events at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference, set to occur from October 29 to November 1 in Madrid, Spain. The conference will feature multiple presentations on new scientific findings from Biogen’s Alzheimer’s research portfolio, with a focus on various treatment aspects and investigations into preclinical Alzheimer’s disease and racial differences.
Priya Singhal, M.D., M.P.H., Head of Development at Biogen, emphasized the significance of this data collection, reflecting the extensive range of their Alzheimer’s research and their ongoing commitment to scientific innovation. Singhal reiterated Biogen's dedication to advancing Alzheimer's research and treatment to benefit the millions of patients, families, and healthcare providers within the Alzheimer's community.
Key presentations and symposia at the conference include:
1. "Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease Treatment Center" on Tuesday, October 29.
2. "The AHEAD 3-45 Study: Design and Results of a Novel Screening Process for a Preclinical AD Trial" on Tuesday, October 29, at 6:10 PM.
3. "Does the Current Evidence Base Support Continued Dosing with Lecanemab for Early Alzheimer's Disease?" on Wednesday, October 30, at 9:40 AM.
4. "Lecanemab for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adults That Are Apoliprotein E ɛ4 Heterozygotes or Non-Carriers" on Wednesday, October 30, at 11:20 AM.
5. "One-Year Experience on the Use of Lecanemab in Clinical Practice" on Wednesday, October 30, at 3:30 PM.
6. "AI-Derived Prognostic Covariates Enhance the Precision of Lecanemab Efficacy Assessments and Optimize Alzheimer's Disease Clinical Trials" on Thursday, October 31, at 3:25 PM.
7. "Estimating by race and APOE Ɛ4 carrier status counts of US adults with subjective cognitive decline with preclinical Alzheimer’s disease" on Friday, November 1.
Additionally, Biogen will host a virtual booth at the conference, offering an interactive medical education module on tau pathophysiology via knowtau.com. This virtual experience will provide further insights into the role of tau in Alzheimer’s disease.
LEQEMBI® (lecanemab) is a product of Biogen's strategic research partnership with Eisai and BioArctic. This humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody targets both soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). In the U.S., LEQEMBI has been approved by the Food and Drug Administration (FDA) for the treatment of Alzheimer's disease since July 6, 2023. The treatment is recommended for patients in the mild cognitive impairment or mild dementia stages, as studied in clinical trials.
Eisai and Biogen have been collaborating on Alzheimer's disease treatments since 2014. Eisai leads the global development and regulatory submission processes for LEQEMBI, with both companies co-commercializing and co-promoting the product. Eisai holds the authority for final decision-making.
Biogen, founded in 1978, is a leading biotechnology company focused on innovative science to develop new medicines that transform patients' lives. The company leverages a deep understanding of human biology to advance first-in-class treatments or therapies with superior outcomes. Biogen balances bold risks with return on investment to achieve long-term growth.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
